Recombinant human serum albumin/pancreatic glucagon peptide fusion protein having blood sugar content continuous control function

A serum albumin and fusion protein technology, applied in the field of long-acting medicinal functions, can solve the problems of limiting the clinical application of GLP-1
CN105884901AActive Publication Date: 2016-08-24BEIJING MEIFUYUAN BIO PHARM TECH +2
16 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
BEIJING MEIFUYUAN BIO PHARM TECH
Publication Date
2016-08-24

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a novel molecular drug structure of recombinant human serum albumin / pancreatic glucagon peptide fusion protein capable of obviously reducing blood sugar content in blood and having continuous effect: rGLP-12 / HSA / GLP-12. Especially, the invention uses a genetic engineering technology for constructing the engineered yeast strain to express the produced recombinant fusion protein. The recombinant fusion protein has the advantages that 1) blood sugar content in the blood is reduced, body weight is reduced, and the recombinant fusion protein is used for treating diabetes and cardiovascular disease; 2) life of pancreatic glucagon peptide is greatly prolonged in vitro and vivo, so that the recombinant fusion protein has maximum stability in the blood and can be continuously effected on the blood sugar control; and 3) saccharomycetes can be used for realizing low-cost large-scale production and preparation process.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention is a continuation application of Chinese patents ZL02142881.6, ZL200410042814.8 and ZL200710057571.9. The invention relates to gene recombination and expressed human serum albumin fusion protein and a preparation method thereof, and relates to a single fusion protein or a method for combining different fusion proteins. In particular, it involves the expression and production of recombinant fusion proteins with different molecular structures formed by human serum albumin and glucagon peptides by yeast, which can be used to control the symptoms of hyperglycemia in patients with type 2 diabetes, preparations for weight loss and prevention of cardiovascular diseases And treatment and long-acting medicinal function with continuous effect. Background technique

[0002] Human serum albumin (HSA) is a soluble monomeric protein that constitutes half of the total protein in blood. As a basic carrier, albumin carries molecules such as fatt...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More